Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · December 21, 2011

Long-Term Posttransplant Bortezomib Boosts Outcome in Myeloma With del(17p13)

Blood

 

Additional Info

Disclosure statements are available on the authors' profiles:

Blood
Administration of Bortezomib Before and After Autologous Stem-Cell Transplantation Improves Outcome in Multiple Myeloma Patients With Deletion 17p
Blood 2011 Dec 08;[EPub Ahead of Print], K Neben, HM Lokhorst, A Jauch, H Goldschmidt, et al

Further Reading